Quality of life measures in irritable bowel syndrome

References

• Drossman DA. Psychosocial considerations in gastroenterology. In: Gastrointestinal Disease: Pathophysiology, Diagnosis, Management (5th Edition). Sleisenger MH, Fordtran JS (Eds). Saunders, PA, USA 3–17 (1993).
   Google Scholar
• Garrett JW, Drossman DA. Health status in inflammatory bowel disease: biological and behavioral considerations. Gastroenterology99, 90–96 (1990).
   PubMed Web of Science ®Google Scholar
• Drossman DA. Psychosocial factors in ulcerative colitis and Crohn’s disease. In: Inflammatory Bowel Disease (4th Edition). Kirsner JB, Shorter RG (Eds). Williams & Wilkins, MD, USA, 492–513 (1995).
   Google Scholar
• Patrick DL, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. Oxford University Press, NY, USA (1993).
   Google Scholar
• Drossman DA, Creed FH, Fava GA et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterol. Int.8, 47–90 (1995).
   Google Scholar
• Drossman DA, Patrick D. Re: Groll et al. – Comparison of IBS-36 and IBS-QoL instruments. Am. J. Gastroenterol.97(12), 3204 (2002).
   PubMed Web of Science ®Google Scholar
• Drossman DA. Presidential address: gastrointestinal illness and biopsychosocial model. Psychosom. Med.60, 258–267 (1998).
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann. Intern. Med.118, 622–629 (1993).
   PubMed Web of Science ®Google Scholar
• Kirshner B, Guyatt G. A methodologic framework for assessing health indices. J. Chronic Dis.38, 27–36 (1985).
   PubMedGoogle Scholar
• Torrance GW. Utility approach to measuring health-related quality of life. J. Chronic Dis.40, 593–600 (1987).
   PubMedGoogle Scholar
• Drossman DA, Leserman J, Mitchell CM, Li Z, Zagami EA, Patrick DL. Health status and health care use in persons with inflammatory bowel disease: a national sample. Dig. Dis. Sci.36, 1746–1755 (1991).
   PubMed Web of Science ®Google Scholar
• Caras S, Krause G, Biesheuvel E, Steinborn C. Cilansetron shows efficacy in non-constipated irritable bowel syndrome patients independent of the definition of the patient population by Rome I or Rome II. Gastroenterology120(Suppl. 1), A217 (2001) (Abstract 1138).
   Web of Science ®Google Scholar
• Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with Alosetron, a 5HT3-receptor antagonist. Aliment. Pharmacol. Ther.13, 1149–1159 (1999).
   PubMed Web of Science ®Google Scholar
• Kellow J, Lee OY, Chang FY et al. An Asia–Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut52, 671–676 (2003).
   PubMed Web of Science ®Google Scholar
• Mangel AW, Hahn BA, Heath AC et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J. Int. Med. Res.26, 76–81 (1998).
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology130, 1538–1551 (2006).
   PubMed Web of Science ®Google Scholar
• Spiegel B, Camilleri M, Bolus R et al. Psychometric evaluation of patient reported outcomes in IBS randomized controlled trials: a Rome foundation working group report. Gastroenterology137, 1944–1953 (2009).
   PubMed Web of Science ®Google Scholar
• Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med. Care27, S217–S232 (1989).
   PubMed Web of Science ®Google Scholar
• Ware JE, Sherbourne CD. The MOS 36-item short form Health Survey (SF-36): I. Conceptual framework and item selection. Med. Care30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer E. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology119, 655–660 (2000).
   Google Scholar
• Bergner M, Bobbitt RA, Carter WB. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care19, 787–805 (1981).
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Leserman J, Toomey TC, Hu Y. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology110, 999–1007 (1996).
   PubMed Web of Science ®Google Scholar
• Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QoL: a disease specific quality of life questionnaire. Am. J. Gastoenterol.95, 999–1007 (2000).
   PubMed Web of Science ®Google Scholar
• Drossman D, Morris CB, Hu Y et al. Characterization of health related quality of life (HRQoL) for patients with functional bowel disorder (FBD) and its response to treatment. Am. J. Gastroenterol.102, 1442–1453 (2007).
   PubMed Web of Science ®Google Scholar
• Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care program. Health Serv. Res.7, 118–133 (1972).
   PubMedGoogle Scholar
• Drossman DA, Morris C, Schneck S et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J. Clin. Gastroenterol.43, 541–550 (2009).
   PubMed Web of Science ®Google Scholar
• Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J. Chronic Dis.40, 171–178 (1987).
   PubMedGoogle Scholar
• Shaw M, Talley NJ, Adlis S, Beebe T, Tomshine P, Healey M. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment. Pharmacol. Ther.12, 1067–1078 (1998).
   PubMed Web of Science ®Google Scholar
• Eypasch E, Wood-Dauphinee S, Williams JI, Ure B, Neugebauer E, Troidl H. Der gastrointestinale lebensqualitatsindex (GLQI). Chirug4, 264–274 (1993).
   Google Scholar
• Svedlund J, Sjodin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci.33, 129–134 (1988).
   PubMed Web of Science ®Google Scholar
• Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development of a new measure. Dig. Dis. Sci.43, 400–411 (1998).
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF et al. Clinical trials: Lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled trials. Aliment. Pharmacol. Ther.29, 329–341 (2009).
   PubMed Web of Science ®Google Scholar
• Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am. J. Gastroenterol.98, 122–127 (2003).
   PubMed Web of Science ®Google Scholar
• Groll D, Vanner SJ, Depew WT et al. The IBS-36: a new quality of life measure for irritable bowel syndrome. Am. J. Gastroenterol.97, 962–971 (2002).
   PubMed Web of Science ®Google Scholar
• Chassany O, Marquis P, Scherrer B et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut44, 527–533 (1999).
   PubMed Web of Science ®Google Scholar
• Chassany O, Geneve J, Abitol JL et al. Specific quality of life questionnaire in irritable bowel syndrome. Effect of fetozidine. Gastroenterology108, A581 (1995).
   PubMed Web of Science ®Google Scholar
• Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment. Pharmacol. Ther.11, 547–552 (1997).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Phillips SF, Melton LJ, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann. Intern. Med.111, 671–674 (1989).
   PubMed Web of Science ®Google Scholar
• Drossman DA. A questionnaire for functional bowel disorders. Ann. Intern. Med.111, 627–629 (1989).
   PubMed Web of Science ®Google Scholar
• Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment. Pharmacol. Ther.11, 553–559 (1997).
   PubMed Web of Science ®Google Scholar
• Wong E, Guyatt GH, Cook DJ, Griffith LE, Irvine EJ. Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur. J. Surg. Suppl.583, 50–56 (1998).
   Google Scholar
• International Foundation for Functional Gastrointestinal Disorders. IBS in the Real World Survey. International Foundation for Functional Gastrointestinal Disorders, WI, USA, 1–20 (2002).
   Google Scholar
• Drossman DA, Corazziari E, Delvaux M et al.Rome III: the functional gastrointestinal disorders (3rd Edition). Rome Foundation, VA, USA, 1377–1556 (2006).
   Google Scholar
• Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther.11, 395–402 (1997).
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Toner BB et al. Functional bowel disorders: a multicenter comparison of health status, and development of illness severity index. Dig. Dis. Sci.40, 986–995 (1995).
   PubMed Web of Science ®Google Scholar
• Levenstein S, Li Z, Almer S et al. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am. J. Gastroenterol.96, 1822–1830 (2001).
   PubMed Web of Science ®Google Scholar
• Wong RK, Drossman DA, Morris CB et al. Partner burden in irritable bowel syndrome. Gastroenterology138(Suppl. 1), S128, A904 (2010).
   Google Scholar